FB23 and FB23-2 are two promising FTO inhibitors, which can selectively inhibit the m6A demethylase activity of FTO, thereby significantly inhibiting the proliferation and promoting apoptosis of AML cells (Huang et al., 2019). Here, FTO is linked to acute myeloid leukemia.